Open Actively Recruiting

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors


Brief Summary

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.

Primary Purpose
Study Type
Phase I


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Key Inclusion Criteria

  • Male and non-pregnant females >18 years old.
  • Patients must have a diagnosis of advanced (primary or recurrent) or metastatic solid tumor with MAPK-pathway alterations as assessed by clinically validated and/or FDA-approved molecular diagnostic and no available standard of care or curative therapies (MAPK-pathway alterations include, for example KRASG12C mutant, EGFR-mutant).
  • Dose expansion only: Patients with specific genomically defined tumor types will be recruited.
  • Patients must have measurable disease by RECIST v1.1.
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
  • Patients must have adequate organ function.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document prior to the initiation of the study and any study procedures.
  • Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures.

Key Exclusion Criteria

  • Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection.
  • Patients with a history of CVA, myocardial infarction or unstable angina within the previous 6 months before starting therapy.
  • Patients with clinically significant cardiac disease.
  • Patients with tumors harboring known activating mutations.
  • Patients with a known additional malignancy that is progressing or requires active treatment.
  • Patients with known central nervous system (CNS) tumors.
  • Patients with known active CNS metastases and/or carcinomatous meningitis.
  • Patients who have previously received a SHP2 inhibitor.
  • Patients with inability to swallow oral medications or with gastrointestinal illness that would preclude the absorption of an oral agent.
  • Patients on dialysis.
  • Patients with a life expectancy of ≤12 weeks after the start of IP according to the investigator's judgement.
  • Patients with known intolerance/hypersensitivity to BBP-398 or its excipients.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Lung Cancer
Rachel Andes
  • UCLA Santa Monica
For Providers
For detailed technical eligibility, visit